Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.

Gilead Sciences (GILD) has reportedly settled a patent lawsuit with the federal government over its HIV drugs Truvada and ...

Gilead's chief executive calls lenacapavir a once in a decade medicine. The HIV treatment could push Gilead stock further up ...

After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a ...

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...

Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its innovative medicines and cell ...

Michael Yee, an analyst from Jefferies, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...

By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...

South San Francisco biotech Pionyr was sold two years ago. Now three of its leaders want to test a trio of drugs beyond ...